FDA Updates Guidance on Pyrogen and Endotoxin Testing

FDA has released an updated version of its guidance on pyrogen and endotoxin testing, offering manufacturers of drugs, biologics, and medical devices greater clarity on regulatory expectations while reinforcing flexibility in testing approaches.

The document, “Pyrogen and Endotoxins Testing—Questions and Answers (Edition 2),” aims to address areas of persistent confusion not fully covered in existing standards such as United States Pharmacopeia (USP) chapters and industry guidelines.

FDA reaffirmed its longstanding acceptance of the Limulus Amebocyte Lysate (LAL) test as a primary method for detecting bacterial endotoxins, a practice in place for decades as an alternative to rabbit pyrogen testing. The agency also formally withdrew its 1987 guidance on LAL validation, stating that newer USP chapters and standards from the Association for the Advancement of Medical Instrumentation now provide sufficient technical detail.

However, the updated guidance supplements those standards by addressing regulatory expectations—particularly around validation, documentation, and lifecycle management of endotoxin testing programs.

Key Clarifications for Industry

Among the most notable updates, FDA outlined expectations across several critical areas:

• Sampling Strategies: Companies are expected to use scientifically justified sampling plans that evolve over time. Initial testing should be broad, with adjustments made as manufacturers gain confidence in process controls. Sampling considerations should include raw materials, in-process stages, and finished products.
• Retesting Protocols: The agency clarified that repeat testing should follow predefined procedures aligned with USP standards. If out-of-specification results cannot be attributed to testing error, product lots may need to be rejected.
• Sample Handling: Proper storage and handling of samples are essential, as endotoxin detection can be affected by environmental and procedural factors. Firms are expected to validate stability and handling procedures.
• Use of Composite Samples: Pooling samples is generally acceptable for certain products, such as small-volume parenterals, but requires careful adjustment of testing parameters to avoid diluting contaminated units. The FDA recommends limiting pooled samples and avoiding pooling in cases where it could mask variability.

FDA reiterated that alternative testing methods may be used if they demonstrate equal or superior performance compared to compendial methods. These alternatives must be validated in accordance with recognized standards and shown to provide reliable results. One example highlighted is the monocyte activation test, which can serve as an alternative to traditional pyrogen testing under appropriate conditions.

For manufacturers adopting new endotoxin testing methods, the agency recommended rigorous comparability studies to demonstrate equivalence. Changes to testing approaches may require regulatory submissions — such as prior approval supplements for drugs and biologics or 30-day notices for certain medical devices — depending on the product classification.

The guidance moves away from outdated fixed tables for endotoxin limits, instead directing firms to calculate limits based on current USP and AAMI methodologies. This reflects the increasing complexity of modern drug formulations and dosing regimens.

FDA also encouraged the application of Quality by Design principles, emphasizing risk-based approaches and in-process controls to prevent endotoxin contamination rather than relying solely on end-product testing.

For medical devices, endotoxin limits depend on the device’s intended use and patient contact. FDA outlined specific thresholds — for example, stricter limits for devices contacting cerebrospinal fluid — and provided recommendations for extraction and testing procedures.

Manufacturers are expected to justify any deviations from standard methods and may need to submit additional regulatory documentation for significant changes, according to the agency.